"Acid Ceramidase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A ceramidase subtype that is active at acid pH. It plays an important role in sphingolipid degradation by catalyzing the lysosomal hydrolysis of ceramide to sphingosine and free fatty acid. Inherited deficiency of acid ceramidase activity results in FARBER LIPOGRANULOMATOSIS.
Below are MeSH descriptors whose meaning is more general than "Acid Ceramidase".
Below are MeSH descriptors whose meaning is more specific than "Acid Ceramidase".
This graph shows the total number of publications written about "Acid Ceramidase" by people in Harvard Catalyst Profiles by year, and whether "Acid Ceramidase" was a major or minor topic of these publication.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
Below are the most recent publications written about "Acid Ceramidase" by people in Profiles.
Design, Synthesis, and Biological Evaluation of a Series of Oxazolone Carboxamides as a Novel Class of Acid Ceramidase Inhibitors. J Med Chem. 2020 12 24; 63(24):15821-15851.
Targeting acid ceramidase inhibits YAP/TAZ signaling to reduce fibrosis in mice. Sci Transl Med. 2020 08 19; 12(557).
Lead Optimization of Benzoxazolone Carboxamides as Orally Bioavailable and CNS Penetrant Acid Ceramidase Inhibitors. J Med Chem. 2020 04 09; 63(7):3634-3664.
Endogenous acid ceramidase protects epithelial cells from Porphyromonas gingivalis-induced inflammation in vitro. Biochem Biophys Res Commun. 2018 01 22; 495(4):2383-2389.
Spinal muscular atrophy with progressive myoclonic epilepsy linked to mutations in ASAH1. Clin Neurol Neurosurg. 2018 01; 164:47-49.
Anticancer actions of lysosomally targeted inhibitor, LCL521, of acid ceramidase. PLoS One. 2017; 12(6):e0177805.
Whole-transcriptome sequencing in blood provides a diagnosis of spinal muscular atrophy with progressive myoclonic epilepsy. Hum Mutat. 2017 06; 38(6):611-614.
Molecular analyses of novel ASAH1 mutations causing Farber lipogranulomatosis: analyses of exonic splicing enhancer inactivating mutation. Clin Genet. 2014 Dec; 86(6):530-8.
GEE-based SNP set association test for continuous and discrete traits in family-based association studies. Genet Epidemiol. 2013 Dec; 37(8):778-86.
Association test based on SNP set: logistic kernel machine based test vs. principal component analysis. PLoS One. 2012; 7(9):e44978.